Why Moderna Could Triple Its COVID Vaccine Sales Next Year

Why Moderna Could Triple Its COVID Vaccine Sales Next Year

When Moderna (NASDAQ: MRNA) provided its fourth-quarter update in February, the biotech stated that it expected $18.4 billion in sales for its COVID-19 vaccine. Since then, Moderna has lined up more supply deals. Here's why Moderna just might be able to triple its COVID vaccine sales next year.